Advertisement
Advertisement
VRCA
Verrica Pharmaceuticals Inc. Common Stock
5.17
USDSponsored
-0.03
-0.50%
Mar 06, 12:54 UTC -5
Open
VRCA Earnings Reports
Positive Surprise Ratio
VRCA beat 16 of 30 last estimates.
53%
Next Report
Next Week
Date of Next Report
Mar 09, 2026
Estimate for Q4 25 (Revenue/ EPS)
$4.62M
/-$0.81
Implied change from Q3 25 (Revenue/ EPS)
-67.82%
/+2600.00%
Implied change from Q4 24 (Revenue/ EPS)
+1241.72%
/-66.25%
Verrica Pharmaceuticals Inc. Common Stock earnings per share and revenue
On Nov 14, 2025, VRCA reported earnings of -0.03 USD per share (EPS) for Q3 25, beating the estimate of -0.68 USD, resulting in a 95.64% surprise. Revenue reached 14.34 million, compared to an expected 5.96 million, with a 140.70% difference. The market reacted with a -5.09% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 7 analysts forecast an EPS of -0.81 USD, with revenue projected to reach 4.62 million USD, implying an increase of 2600.00% EPS, and decrease of -67.82% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Harrow, Inc. Common Stock
Report Date
Mar 02, 2026 For Q4 25
Estimate
$0.37
Actual
$0.26
Surprise
-30.87%
Amylyx Pharmaceuticals, Inc. Common Stock
Report Date
Mar 03, 2026 For Q4 25
Estimate
-$0.36
Actual
-$0.30
Surprise
+18.50%
Xeris Biopharma Holdings, Inc. Common Stock
Report Date
Mar 02, 2026 For Q4 25
Estimate
$0.04
Actual
$0.06
Surprise
+33.63%
Bioventus Inc. Class A Common Stock
Report Date
Mar 05, 2026 For Q4 25
Estimate
$0.21
Actual
$0.24
Surprise
+9.69%
Altimmune, Inc. Common Stock
Report Date
Mar 05, 2026 For Q4 25
Estimate
-$0.24
Actual
-$0.27
Surprise
-10.16%
Aquestive Therapeutics, Inc. Common Stock
Report Date
Mar 04, 2026 For Q4 25
Estimate
-$0.13
Actual
-$0.26
Surprise
-92.31%
OmniAb, Inc. Common Stock
Report Date
Mar 04, 2026 For Q4 25
Estimate
-$0.09
Actual
-$0.11
Surprise
-21.82%
Profound Medical Corp. Common Stock
Report Date
Mar 05, 2026 For Q4 25
Estimate
-$0.26
Actual
-$0.27
Surprise
-0.26%
MediWound Ltd.
Report Date
Mar 05, 2026 For Q4 25
Estimate
-$0.64
Actual
-$0.56
Surprise
+13.08%
Cumberland Pharmaceuticals Inc
Report Date
Mar 03, 2026 For Q4 25
Estimate
-Actual
-$0.01
Surprise
-
FAQ
What were Verrica Pharmaceuticals Inc. Common Stock's earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, Verrica Pharmaceuticals Inc. Common Stock reported EPS of -$0.03, beating estimates by 95.64%, and revenue of $14.34M, 140.7% above expectations.
How did the market react to Verrica Pharmaceuticals Inc. Common Stock's Q3 2025 earnings?
The stock price moved down -5.09%, changed from $3.93 before the earnings release to $3.73 the day after.
When is Verrica Pharmaceuticals Inc. Common Stock expected to report next?
The next earning report is scheduled for Mar 09, 2026.
What are the forecasts for Verrica Pharmaceuticals Inc. Common Stock's next earnings report?
Based on 7
analysts, Verrica Pharmaceuticals Inc. Common Stock is expected to report EPS of -$0.81 and revenue of $4.62M for Q4 2025.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement